Medios Takes Over Dutch Leader in Pharmaceutical Compounding Services

• Medios AG acquires Ceban Pharmaceuticals B.V., a pharmaceutical compounding platform in the Netherlands, Belgium, and Spain - The acquisition is expected to generate revenue of €160 million in 2023 with an EBITDA of €29 million - The purchase price includes €235.3 million in cash and 1.7 million new Medios shares valued at €23.9 million - The transaction is financed by existing cash and a €200 million credit facility - The completion of the acquisition is expected in the second quarter of 2024 - Medios expects revenue in FY 2024 to reach €1.9 to €2.1 billion with an EBITDA of €82 to €91 million, based on the acquisition of Ceban in Q2

The price of Medios at the time of the news was 13,950EUR and was down -0,07 % compared with the previous day.

Medios

-1,39 %

-2,05 %

-13,65 %

-3,77 %

-23,53 %

-59,72 %

-18,75 %

+43,82 %

ISIN:DE000A1MMCC8WKN:A1MMCC

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max